Evidence map›Paper›PMID 24651255›Full record

ArticleScientific reports2014

Novel multiplex MethyLight protocol for detection of DNA methylation in patient tissues and bodily fluids.

Ekaterina Olkhov-Mitsel, Darko Zdravic, Ken Kron, Theodorus van der Kwast, Neil Fleshner, Bharati Bapat

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 50 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Ekaterina Olkhov-Mitsel1] Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada [2] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Darko Zdravic1] Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada [2] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.
Ken KronOntario Cancer Institute, Princess Margaret Cancer Center-University Health Network, Toronto, ON, Canada.
Theodorus van der Kwast1] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada [2] Department of Pathology and Laboratory Medicine, University Health Network, Toronto, Ontario, Canada.
Neil FleshnerDepartment of Urology, University Health Network, Toronto, ON, Canada.
Bharati Bapat1] Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada [2] Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada [3] Department of Pathology and Laboratory Medicine, University Health Network, Toronto, Ontario, Canada.
Mount Sinai Hospital · CAUniversity Health Network · CALunenfeld-Tanenbaum Research Institute · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant DNA methylation is a hallmark of cancer and is an important potential biomarker. Particularly, combined analysis of a panel of hypermethylated genes shows the most promising clinical performance. Herein, we developed, optimized and standardized a multiplex MethyLight assay to simultaneously detect hypermethylation of APC, HOXD3 and TGFB2 in DNA extracted from prostate cancer (PCa) cell lines, archival tissue specimens, and urine samples. We established that the assay is capable of discriminating between fully methylated and unmethylated alleles with 100% specificity and demonstrated the assay as highly accurate and reproducible as the singleplex approach. For proof of principle, we analyzed the methylation status of these genes in tissue and urine samples of PCa patients as well as PCa-free controls. These data show that the multiplex MethyLight assay offers a significant advantage when working with limited quantities of DNA and has potential applications in research and clinical settings.

Indexed as

DNA MethylationAdenomatous Polyposis Coli ProteinCell Line, TumorCpG IslandsDNA, NeoplasmDNA PrimersHomeodomain ProteinsHumansMaleMultiplex Polymerase Chain ReactionPromoter Regions, GeneticProstatic NeoplasmsReproducibility of ResultsSensitivity and SpecificityTranscription FactorsTransforming Growth Factor beta2Adenomatous Polyposis Coli ProteinAPC protein, humanDNA, NeoplasmDNA PrimersHomeodomain ProteinsHOXA4 protein, humanTGFB2 protein, humanTranscription FactorsTransforming Growth Factor beta2

Identifiers

PMID24651255
PMCPMC3961737
OpenAlexW1977286905

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.